Sanara MedTech (NASDAQ:SMTI) Announces Earnings Results, Beats Estimates By $0.07 EPS

Sanara MedTech (NASDAQ:SMTI) announced its quarterly earnings data on Tuesday. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.07, Zacks reports. Sanara MedTech had a negative net margin of 31.23% and a negative return on equity of 3.19%. The firm had revenue of $28.14 million during the quarter, compared to analysts’ expectations of $28.95 million.

Sanara MedTech Stock Performance

Shares of NASDAQ:SMTI traded down $0.12 during trading hours on Wednesday, hitting $34.26. The stock had a trading volume of 100,629 shares, compared to its average volume of 97,945. Sanara MedTech has a 1-year low of $16.05 and a 1-year high of $35.95. The firm has a market capitalization of $313.96 million, a price-to-earnings ratio of -9.09 and a beta of 1.12. The stock’s fifty day simple moving average is $25.66 and its 200 day simple moving average is $21.89. The company has a debt-to-equity ratio of 6.59, a quick ratio of 2.05 and a current ratio of 2.28.

Wall Street Analyst Weigh In

Several research analysts have commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Sanara MedTech in a report on Friday, July 17th. Wall Street Zen cut Sanara MedTech from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 1st. Freedom Capital cut Sanara MedTech from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 3rd. Lake Street Capital lowered Sanara MedTech from a “buy” rating to a “hold” rating and set a $35.00 target price on the stock. in a research report on Thursday, July 30th. Finally, HC Wainwright cut Sanara MedTech from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $36.00 to $35.00 in a research note on Thursday, July 30th. Four analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce” and a consensus price target of $35.00.

Hedge Funds Weigh In On Sanara MedTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in SMTI. BNP Paribas Financial Markets grew its holdings in shares of Sanara MedTech by 351.7% during the third quarter. BNP Paribas Financial Markets now owns 1,504 shares of the company’s stock valued at $48,000 after buying an additional 1,171 shares in the last quarter. Wells Fargo & Company MN grew its stake in Sanara MedTech by 78.1% in the fourth quarter. Wells Fargo & Company MN now owns 3,322 shares of the company’s stock valued at $78,000 after purchasing an additional 1,457 shares in the last quarter. Lazard Asset Management LLC raised its stake in shares of Sanara MedTech by 63,100.0% during the 2nd quarter. Lazard Asset Management LLC now owns 3,160 shares of the company’s stock worth $89,000 after purchasing an additional 3,155 shares in the last quarter. Deutsche Bank AG grew its stake in shares of Sanara MedTech by 171.1% in the 4th quarter. Deutsche Bank AG now owns 3,985 shares of the company’s stock valued at $93,000 after buying an additional 2,515 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in Sanara MedTech by 44.1% during the 3rd quarter. Bank of America Corp DE now owns 3,181 shares of the company’s stock valued at $101,000 after purchasing an additional 973 shares during the last quarter. 8.10% of the stock is currently owned by hedge funds and other institutional investors.

Sanara MedTech Company Profile

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.